ABSTRACT
Objective To investigate the curative effect of mesalamine combined with trimebutine maleate in the treatment of diarrhea predominant irritable bowel syndrome .Methods According to the digital table ,112 patients with diarrhea predominant irritable bowel syndrome were randomly divided into control group and observation group , 56 cases in each group .The two groups were given conventional symptomatic treatment ,on this basis ,the control group recieved mesalamine treatment ,the observation group recieved mesalamine combined with trimebutine maleate treat -ment.The two groups were treated for 4 consecutive weeks.The main indicators,clinical efficacy and adverse reaction of the two groups were compared .Results The total effective rate of the observation group was 94.6％,which was significatnly higher than 78.6％of the control group (χ2 =3.925,P<0.05).The antidiarrheal time,stool recovery time between the two groups had statistically significant differences (t=19.337,18.068,all P<0.05).The mental status,emotional status,diet and sleep status in the two groups were all improved ,the differences were statistically significant(all P<0.05),which in the observation group improved more significantly than that in the control group , the differences were statistically significant(all P<0.05).The two groups had no other serious adverse reactions . Conclusion On the basis of conventional treatment ,mesalamine combined with trimebutine maleate in the treatment of diarrhea predominant irritable bowel syndrome can significantly improve clinical symptoms ,improve clinical curative effect,and it has good safety and great clinical significance .
ABSTRACT
Objective To study the clinical efficacy of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with trimebutine maleate and psychological intervention in the treatment of functional diarrhea. Methods 100 patients with functional diarrhea treated in our hospital from May 2015 to August 2016 were selected and randomly divided into the control group and the experimental group, with 50 patients in each group. The control group were treated with trimebutine maleate treatment, the experimental group were treated with live combined bacillus subtilis and enterococcus faecium enteric-coated capsules trimebutine therapy and psychological intervention, pay attention to the psychological status of patients and patients, strengthen communication and exchanges, increase confidence in the treatment and the treatment compliance of patients. The therapeutic effects of the experimental group and the control group were compared and analyzed. Results After the corresponding treatment, the effective rate was 92.0％ in the experimental group and 84.0％ in the control group. The difference was statistically significant (P<0.05). There was no obvious adverse reaction in the experimental group and the control group. After treatment, the number of diarrhea in the experimental group was (3.0±0.3), significantly less than that of the control group (4.3±0.3), the difference was statistically significant (P<0.05). Conclusion The clinical effect of live combined bacillus subtilis and enterococcus faecium enteric-coated capsules combined with trimebutine maleate and psychological intervention in the treatment of functional diarrhea is good, can improve clinical symptoms in a large extent, has the meaning of promotion.
ABSTRACT
Objective To study the effect of Trimebutine maleate tablets on serum tumor necrosis factor(TNF)-α,interleukin(IL)-23,erythrocyte sedimentation rate(ESR),D-dimer(D-D)ulcerative colitis in patients with ulcerative colitis.Methods 92 patients of ulcerative colitis who received therapy from October 2014 to October 2016 in our hospital were selected.According to random number table,those patients were divided into the observation group(n=46)and the control group(n=46).The control group was treated with mesalazine slow release tablets,while the observation group was treated with trimebutine maleate tablets on this basis.After 8 weeks of treatment,the changes of the disease activity index(Sutherland DAI score),TNF-α,IL-23,ESR,D-D and clinical effect were compared.Results After treatment,the Sutherland DAI score in the observation group was significantly lower than that of the control group DAI(P<0.05); the TNF-αand IL-23 in the observation group were significantly lower than that of the control group(all P<0.05); the ESR and D-D in the observation group were significantly lower than that of the control group(all P<0.05); the total effective rate in the observation group was significantly higher than that of the control group[93.48％(43/46)vs.69.57％(32/46)](P<0.05).Conclusion Trimebutine maleate tablets is well for ulcerative colitis,which can effectively reduce inflammation,improve hypercoagulable state,promote the recovery of the disease,it is worthy of application and promotion.
ABSTRACT
Objective To investigate the effect of Trimebutine maleate on reflux esophagitis in elderly patients.Methods A total of 160 elderly patients with typical esophageal reflux symptoms diagnosed as reflux esophagitis by gastroscope,with concomitant gastroesophageal disease confirmed by esophageal motility manometry and 24 h esophageal pH impedance monitoring acid reflux,were selected and retrospectively analyzed.All patients were treated with proton pump inhibitor(PPI) esomeprazole 20 mg tid,antecibum(AC)for 8 weeks,and randomly divided into four groups:group A (itopride hydrochloride 50 mg tid,AC),group B(citrate mosapride 5 mg tid,AC),group C (trimebutine maleate 200 mg tid,AC),group D(treated without prokinetic drugs).After 4 and 8 weeks of therapy,the symptom improvements were observed in the four groups.Endoscopy,esophageal motility manometry,24h esophageal pH impedance monitoring were performed in the 160 cases after 8 weeks of treatment.Results The total effective rate was 97.5％(39 cases),95.0％ (38 cases),92.5％(37 cases)and 77.5％(31 cases)in group A,B,C and D respectively after 8 weeks of treatment.Endoscopic examination showed that the cure rate was 70.0％ (28 cases),62.5％ (25cases),72.5％(29 cases),67.5％(27 cases),and the effective rate was 87.5％,(35 cases),92.5％(37 cases),87.5％(35 cases)and 87.5％(35 cases)in group A,B,C and D respectively after 8 weeks of treatment,without statistically significant differences in the cure rate and effective rate between the four groups.The results of esophageal motility manometry showed that the lower esophageal sphincter pressure(LESP),lower esophageal sphincter relaxation (LESR),lower esophageal peristaltic wave pressure(LEPP) and percentage of abnormal esophageal body contraction had significant difference before versus after treatment in group A and B,but not in control group.The improvements in the percentage of total time of pH＜4.0,the percentage of time of pH＜4 at standing position,the percentage of time of pH＜4 at supine position,supine reflux times,the times of supine reflux＞5 min,the longest reflux time(min)at supine position were more significant in group A,B and C than in group D.Compared with pre-treatment,the times of non-acid reflux were reduced significantly in group A,B and D(all P＜0.01),and there was a significant difference(P＜0.05)between the three (A,B,C)groups and group D(P＜0.05).There were significant differences in the times of reflux liquid and gas reflux between the group A,B and D(P＜0.05).The proximal reflux times were improved more significantly in group A,B and C after treatment than in control group(P＜0.05).Conclusions Prokinetic drugs combined with PPI therapy has better effect than single PPI application in improving the clinical symptoms and upper gastrointestinal motility in elderly patients with RE.Trimebutine maleate is safe and effective in the elderly,and has a similar effect on esophageal motility with mosapride citrate and itopride hydrochloride,which may be involved in selectively improving esophageal motility,lower esophageal sphincter pressure and gastric emptying function.
ABSTRACT
Objective To explore the clinical effect of flupentixol and melitracen(deanxit)combined with trimebutine maleate(TMB)in the treatment of patients with functional gastrointestinal disorders(FGID).Methods 135 patients with FGID were selected,and were divided into two groups accorded to the random number method,with 68 cases in the observation group and 67 cases in the control group.The control group was treated with oryzanol and vitamin B6 ,while the observation group was treated with deanxit combine with TMB on the basis of the control group. Main symptoms of postprandial discomfort,early satiety,abdominal pain and burning sensation on the abdomen in the two groups before and after treatment were monitored,adverse reactions of two groups were recorded,and the total efficacy was evaluated after the end of treatment.Results The difference of postprandial discomfort,early satiety, abdominal pain and upper abdominal burning sensation integration between the two groups had no statistically significant before treatment(all P >0.05).After treatment,the postprandial discomfort,early satiety,the abdominal pain and epigastric burning sensation were (4.1 ±1.6)points,(3.4 ±1.1)points,(4.2 ±1.2)points and(4.4 ± 0.7)points in the observation group,which were better than (5.9 ±2.4)points,(5.3 ±1.6 )points,(6.0 ± 1.2)points and(6.1 ±0.5)points in the control group(t =3.057,4.791,5.196,9.681,all P 0.05).Conclusion Deanxit combine with TMB can significantly improve symptoms in patients with FGID,and has a significant effect,thus it is a safe and effective therapy.
ABSTRACT
Objective To discuss the efficacy and pharmacological mechanism of Simo decoction to assist the treatment of postoperative gastrointestinal dysfunction. Methods 200 mice (100 male and 100 female) were randomly divided into four groups (n=50). The mice of blank group were feed as normal,and the mice in the other three groups were prepared for colon postoperative gastrointestinal dysfunction model. Then,trimebutine maleate group were given trimebutine maleate while the combined group were given trimebutine maleate and simo decoction through gavage,and model group and blank group were given the same doses of distilled water. One week later,the abdominal ve-nous blood of mice was extracted and serum levels of acetylcholine ( ACH) and norepinephrine ( NE) were detected using ELISA kit. At the samd time,the gastric emptying and intestinal propulsion experiment was carried on. Results After modeling,compared with blank group, MUPA of the rest three groups were significantly decreased (P0. 05). After drug intervention,MUPA of trimebutine maleate group was significantly higher than that of model group,and MUPA of combined group was significantly higher than that of trimebutine maleate group (P<0. 05). In addition,compared with blank group,the gas-tric emptying rate,intestinal propulsion rate,serum ACH concentration and NE concentration of the rest three groups were significantly lower (P<0. 05). Compared with model group,each index of both trimebutine maleate group and combined group was increased,and combined group increased higher (P<0. 05). Conclusion Simo decoction combined trimebutine maleate has high effect to improve the level of ACH and NE of postoperative gastrointestinal dysfunction mice,which benefit to promote gastrointestinal peristalsis and may be one of its pharmaco-logical mechanisms.
ABSTRACT
OBJECTIVE: According to the feature that trimebutine maleate has poor aqueous solubility, low bioavailability when taken orally, short biological half-life (2.7 h), sustained-release dropping pills were prepared to achieve release slowly, reduce the blood drug concentration fluctuations and decrease frequency of use.
ABSTRACT
Objective To validate the clinical safety and efficacy of trimebutine maleate in the treatment of functional dyspepsia(FD).Methods 64 patients with FD were recruited into the study and ramdomly divided into two groups,each 32 examples.The observed group was given trimebutine maleate 200mg,po,tid,and the matched group was given oryzanol 10mg po,tid.The treatment circumstance was recorded one day before the treatment,and once a week for two weeks.Results After 2 weeks observation,drug efficacy to the symptom of naupathia,abdominal pain,diarrhoea and constipation were 86.7%,90.4%,84.6% and 85.7%,respectively.The observed group had gross efficiency for 82%,with the machted group for 54.0%.No side effect was observed.Conclusion Trimebutine is an effective agent for treatment of FD,and has no obvious side effect.
ABSTRACT
OBJECTIVE: To assess the efficacy and safety of compound azintamide and trimebutine maleate in the treatment of functional dyspepsia (FD) in elderly patients. METHODS: 48 elderly patients with FD up to Rome Ⅲ were randomly divided into two groups. Treatment group were given 200 mg trimebutine maleate tid at 15 min before meal and 2 pieces of compound azintamide tid after meal for 4 weeks (n=23). Control group were given 200 mg trimebutine maleate tid for 4 weeks (n=25). Questionnaire survey was applied to detect the index of dyspeptic symptoms and drug toxity before and after treatment. RESULTS: The patients with FD in two groups were matched well in respect of age, sex and index of dyspeptic symptoms. Routine therapy was achieved and adverse reaction wasn’t found. Curative efficacy and symptom score in treatment group were significantly better than in control group after 4 weeks of treatment, such as poor appetite, abdominal distension, early satiety, belching , except upper abdominal pain and burning sensation (P
ABSTRACT
AIM: To investigate the clinical efficacy of trimebutine maleate combined with Morita therapy in the treatment of patients with irritable bowel syndrome (IBS). METHODS: 108 patients were randomly assigned to two groups. Trimebutine maleate group (n=54) was given trimebutine maleate 200 mg, po, tid, combined with Mortia therapy. The patients were analyzed by self rating anxiety scale (SAS) and self rating depression scale (SDS) before and after the treatment. Control group (n=54) was only given trimebutine maleate 200 mg, po, tid. The course was 4 weeks. RESULTS: The total efficacy rates were 87.04 % and 72.22 % in trimebutine maleate group and in control group, respectively. The therapeutic effects in trimebutine maleate group were better than those in the control group (P